Anti-IL-6R Antibody, clone 1D19 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1D19 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects IL-6R. It targets an epitope within 18 amino acids from the extracellular domain.

KLH-conjugated linear peptide corresponding to 18 amino acids from the extracellular domain of human IL-6R.

Quality Control Testing

Evaluated by Western Blotting with recombinant human IL-6R.

Western Blotting: A 1:10,000 dilution of this antibody detected recombinant human IL-6R.

Tested Applications

Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected IL-6R in U266B1 cell lysate.

Flow Cytometry Analysis: 1 µg from a representative lot detected IL-6R in one million human peripheral blood mononuclear cells (PBMC).

Affinity Binding Assay: A representative lot of this antibody bound IL-6R peptide with at least one thousand-fold (1,000X) higher than with non-specific control peptide.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected IL-6R in U937 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected IL-6R in human spleen, human tonsil, human testis cancer, and human liver cancer tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Interleukin-6 receptor subunit alpha (IL-6R) (UniProt: P08887; also known as IL-6 receptor subunit alpha, IL-6R subunit alpha, IL-6R-alpha;IL-6RA, IL-6R 1, Membrane glycoprotein 80 (gp80), Soluble interleukin-6 receptor subunit alpha, sIL6R, CD126) is encoded by the IL6R gene (Gene ID: 3570) in human. IL-6R is a component of the IL-6 receptor complex. It composed of an extracellular domain that binds IL-6, a transmembrane domain, and a relatively short cytoplasmic tail that does not have intrinsic signaling capability. Upon Il-6 binding, IL-6R pairs with the glycoprotein 130 (gp130) co-receptor, leading to the activation of various intracellular signaling pathways, including JAK/STAT, MAPK, and PI3K-Akt. These pathways regulate gene expression involved in immune response, inflammation, cell survival, proliferation, and differentiation. IL-6R is expressed in a variety of cell types, including immune cells like T cells, B cells, and macrophages, as well as liver and some endothelial cells. The expression can be regulated by inflammatory stimuli, which enhances the responsiveness of cells to IL-6 during inflammation or infection. IL-6R is primarily localized on the cell surface where it interacts with circulating IL-6. However, a naturally occurring soluble form of IL-6R (sIL-6R) also exists, generated either by alternative splicing or by proteolytic cleavage of the membrane-bound receptor. This soluble receptor can bind IL-6 and activate cells via gp130, even in the absence of membrane-bound IL-6R, a process known as trans-signaling. IL-6R plays a significant role in the pathogenesis of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, Castleman′s disease, and systemic lupus erythematosus. Overactivation of IL-6/IL-6R signaling is linked to chronic inflammation and autoimmunity. Targeting IL-6R with therapeutic antibodies like tocilizumab, which blocks IL-6R, has proven effective in treating these conditions. Additionally, increased levels of sIL-6R are associated with severe asthmatic symptoms and other inflammatory disorders. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.